Skip to main content
. 2019 Apr 23;9:6428. doi: 10.1038/s41598-019-41444-2

Figure 5.

Figure 5

Fraxini regulated c-Myc stability in Hep3B cells. (A) Expression of c-Myc mRNA in Fraxini-treated Hep3B cells. (B) Cycloheximide (CHX) chase assay showing the half-life of c-Myc protein. (C) c-Myc expression in Hep3B cells treated with or without proteasome inhibitor MG-132 (400 nM). (D) Fraxini-regulated phosphorylation of c-Myc. (E) Growth curve of Fraxini-treated Burkitt lymphoma cells (Raji cells), which are known to carry T58 mutant CMYC. (F) Expression of c-Myc in Raji cells treated with Fraxini. Abbreviations: min, minute; p-, phosphorylated; T1/2, half-life of c-Myc.